Natera, Inc. (NTRA) – What Are Analysts Saying About This Stock?

Posted by Geri Gentry on Nov 11th, 2026

Shares of Natera, Inc. (NASDAQ:NTRA – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty-three analysts that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, seventeen have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $394.31.

A number of research firms have recently weighed in on NTRA. Canaccord Genuity Group lifted their price target on shares of Natera from $375.00 to $500.00 and gave the company a “buy” rating in a research report on Monday, October 19th. Leerink Partners set a $330.00 price target on Natera in a research report on Friday, August 7th. Piper Sandler restated an “overweight” rating and set a $363.50 price objective on shares of Natera in a research note on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Thursday, October 15th. Finally, Rothschild & Co Redburn started coverage on Natera in a report on Tuesday, September 8th. They issued a “buy” rating and a $385.00 price objective for the company.

View Our Latest Analysis on Natera

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

Positive Sentiment: Third-quarter revenue rose 34.1% to about $794 million, beating estimates, and Natera raised its 2026 sales outlook as test volumes—particularly oncology testing—accelerated. NTRA Q3 Loss Wider Than Expected, Revenues Beat, ’26 Sales View Up
Positive Sentiment: Management highlighted a long-term goal of $6 billion in revenue by 2029, supported by Signatera growth, broader reimbursement and continued investment. Natera Q3 Earnings Call Highlights $6B Target & Raised 2026 Outlook
Positive Sentiment: Natera is collaborating with Incyte on a Phase 2 colorectal cancer trial, which could support its oncology testing business, though the commercial impact will depend on trial results and adoption. Natera Launching Collaboration With Incyte for Phase 2 Trial to Treat Colorectal Cancer
Neutral Sentiment: A report listed short interest at zero shares as of November 10, a figure that does not indicate meaningful short positioning; the report’s description of a significant increase appears inconsistent with that number.
Negative Sentiment: Despite the revenue beat, Natera’s quarterly loss of $0.42 per share was wider than the $0.28 loss analysts expected, highlighting ongoing profitability concerns. NTRA Q3 Loss Wider Than Expected, Revenues Beat, ’26 Sales View Up
Negative Sentiment: Analysts cut price targets, including Robert W. Baird’s reduction to $403 from $458, while maintaining an Outperform rating. JPMorgan also reportedly lowered its target, adding a cautious note despite the improved outlook. Robert W. Baird Stock Recommendations Natera Stock Gets Price Target Cut from JPMorgan Chase & Co.

Insider Buying and Selling at Natera

In related news, insider Solomon Moshkevich sold 15,160 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the completion of the sale, the insider directly owned 110,859 shares in the company, valued at $36,238,698.51. This represents a 12.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Chapman sold 3,801 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $411.80, for a total value of $1,565,251.80. Following the completion of the sale, the chief executive officer directly owned 87,431 shares in the company, valued at $36,004,085.80. This trade represents a 4.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 47,056 shares of company stock valued at $17,760,989 in the last ninety days. 5.05% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Natera

Hedge funds have recently made changes to their positions in the stock. Trust Co. of Vermont acquired a new position in shares of Natera during the second quarter worth $26,000. Elevation Wealth Partners LLC bought a new stake in Natera during the 2nd quarter worth $30,000. Continuum Advisory LLC bought a new stake in Natera during the 2nd quarter worth $33,000. International Assets Investment Management LLC increased its holdings in Natera by 132.9% in the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after purchasing an additional 97 shares in the last quarter. Finally, Rakuten Securities Inc. acquired a new position in Natera in the 2nd quarter worth about $35,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Down 2.6%

Shares of NASDAQ:NTRA opened at $311.98 on Wednesday. Natera has a 12-month low of $181.00 and a 12-month high of $437.41. The business has a 50 day moving average of $379.93 and a 200-day moving average of $270.42. The stock has a market cap of $45.24 billion, a PE ratio of -273.67 and a beta of 1.55.

Natera (NASDAQ:NTRA – Get Free Report) last announced its earnings results on Thursday, November 5th. The medical research company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). Natera had a negative return on equity of 8.61% and a negative net margin of 5.66%. The firm had revenue of $793.98 million for the quarter, compared to the consensus estimate of $707.54 million. During the same quarter last year, the business posted ($0.64) EPS. Natera’s revenue for the quarter was up 34.1% on a year-over-year basis. Equities research analysts expect that Natera will post -1.20 earnings per share for the current year.

Natera Company Profile

(Get Free Report)

Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.